GlassScriptPhysician profile
Maria Sukhoo
NPI 1619435245
$11,138.15
in general payments reported to CMS, 2019-2025
34 companies · $2,137 in 2025
The $2,137 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.25 · 2022: $375 · 2023: $3,663 · 2024: $4,939 · 2025: $2,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,519.10 |
| Education | $219.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,286.10 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,592.99 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $877.33 | 2023-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $671.72 | 2023-2025 | Jardiance, Stiolto Respimat, Synjardy |
| Lilly USA, LLC | $584.87 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $557.42 | 2022-2025 | Veozah, Myrbetriq |
| Medtronic, INC. | $524.82 | 2023-2025 | Intellis Adaptivestim, Synchromedii |
| Novartis Pharmaceuticals Corporation | $514.44 | 2022-2025 | |
| Vivus LLC | $381.19 | 2022-2025 | Pancreaze, Qsymia |
| Bayer Healthcare Pharmaceuticals INC. | $348.61 | 2022-2024 | |
| Nevro Corp. | $347.69 | 2022-2023 | Senza |
| Abbott Laboratories | $328.84 | 2024-2025 | Freestyle Libre 3, Eterna |
| Heartflow, INC. | $324.03 | 2024 | |
| Abbvie INC. | $229.14 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $220.78 | 2024 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $215.53 | 2023 | Xarelto |
| Davol INC. | $161.85 | 2024 | Phasix Mesh |
| Boston Scientific Corporation | $136.58 | 2024 | Intracept |
| Averitas Pharma INC. | $121.11 | 2023 | Qutenza |
| Dexcom, INC. | $109.95 | 2024-2025 | Dexcom G6 Transmitter |
| Intuitive Surgical, INC. | $109.93 | 2024 | |
| Procept Biorobotics Corporation | $100.23 | 2024 | Aquabeam System |
| Amarin Pharma, INC. | $85.98 | 2022-2023 | |
| Stryker Corporation | $55.22 | 2025 | Mild Device Kit |
| Spinal Simplicity, LLC | $45.69 | 2025 | Ha Minuteman G3-R |
| Glaxosmithkline, LLC. | $39.84 | 2022-2023 | Trelegy Ellipta |
| Currax Pharmaceuticals LLC | $30.83 | 2024-2025 | Contrave |
| Eisai INC. | $24.53 | 2022 | |
| Edwards Lifesciences Corporation | $24.25 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.01 | 2025 | Keveyis |
| Exact Sciences Corporation | $21.32 | 2023 | Cologuard Collection Kit |
| Alvogen INC | $16.33 | 2022 | |
| Ucb, INC. | $14.33 | 2022 | |
| Aurinia Pharma U.S., INC. | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Sukhoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.